MARKET

MYGN

MYGN

Myriad Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.38
+1.73
+6.74%
After Hours: 27.38 0 0.00% 16:59 05/14 EDT
OPEN
25.71
PREV CLOSE
25.65
HIGH
27.40
LOW
25.49
VOLUME
555.13K
TURNOVER
--
52 WEEK HIGH
33.97
52 WEEK LOW
10.54
MARKET CAP
2.11B
P/E (TTM)
-12.1884
1D
5D
1M
3M
1Y
5Y
Glenview's Robbins pitches SPACs Fortress Value, Thoma Bravo at Sohn conference
Hedge fund manager Larry Robbins pitched SPACs Fortress Value Acquisition Corp. II (FAII), Thoma Bravo Advantage (TBA) and Fast Acquisition Corp. (FST).While Robbins joked that SPACs are now a four
Seekingalpha · 3d ago
Genetic Testing Market Size, Volume By Types, Key Players, Trend, Share, Production, Import, Export, Consumption, Data Analysis, and Forecast 2021 – 2023
May 12, 2021 (The Expresswire) -- Global "Genetic Testing Market" research analysis is provided on major factors such as consumer needs and changes observed...
The Express Wire · 4d ago
Global Companion Diagnostics Market Trend 2021-2025 with Top-Countries Data And Covid-19 Analysis, Industry Overview, Key Players Analysis, Emerging Opportunities, Comprehensive Research, Competitive Landscape and Potential of Industry from
May 12, 2021 (The Expresswire) -- Global “Companion Diagnostics Market” Report 20212025 covers the worldwide and regional market with an in-depth analysis...
The Express Wire · 4d ago
Liquid Biopsy Market 2021 with Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Value & Volume, Price, Cost and Gross Margin 2021-2024
May 11, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global "Liquid Biopsy Market" report...
The Express Wire · 5d ago
Global Cancer Diagnostics Market Outlook, Industry Analysis and Prospect 2026
May 11, 2021 (Heraldkeepers) -- The understanding of the pathways of cancer development and their causes has led to the development of novel methodologies,...
Heraldkeepers · 5d ago
Global Genomics Market Outlook, Industry Analysis and Prospect 2027
May 11, 2021 (Heraldkeepers) -- Genomics is the branch of biotechnology where different techniques of genetics and molecular biology are employed to map the...
Heraldkeepers · 5d ago
Pharmacogenomics Market Size, Share, Trends, Analysis and Forecast 2027
May 10, 2021 (Market Insight Reports) -- The Global Pharmacogenomics Market is estimated to value over USD 11.5 billion by 2027 end at a CAGR of over 8.5%...
Market Insight Reports · 5d ago
Breast Cancer Diagnostics Global Market Report 2021: COVID 19 Growth And Change to 2030
Reportlinker.com announces the release of the report "Breast Cancer Diagnostics Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06071101/?utm_source=GNW
GlobeNewswire · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MYGN. Analyze the recent business situations of Myriad Genetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MYGN stock price target is 26.86 with a high estimate of 37.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 327
Institutional Holdings: 87.96M
% Owned: 114.15%
Shares Outstanding: 77.05M
TypeInstitutionsShares
Increased
38
1.88M
New
24
547.61K
Decreased
43
1.26M
Sold Out
18
311.03K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.22%
Healthcare Equipment & Supplies
+1.17%
Key Executives
Chairman/Independent Director
S. Louise Phanstiel
President/Chief Executive Officer/Director
Paul Diaz
Chief Financial Officer/Executive Vice President/Treasurer
R. Bryan Riggsbee
Corporate Executive
Nicole Lambert
Corporate Executive
Mark Verratti
Corporate Executive
Faith Zaslavsky
Executive Vice President/General Counsel/Secretary
Benjamin Jackson
Executive Vice President/Director of Human Resources
Jayne Hart
Executive Vice President
Paul Parkinson
Senior Vice President/Chief Marketing Officer
Jeff Borcherding
Senior Vice President
Maggie Ancona
Other
Mark Pollack
Senior Vice President
Edward Gala
Independent Director
Heinrich Dreismann
Senior Vice President
David Hammer
Senior Vice President
Chris Williamson
Chief Technology Officer
Kevin Haas
Chief Scientific Officer
Jerry Lanchbury
Vice President
Justin Hunter
Vice President
Karen Renner
Vice President - Business Development
Jackie Zou
Other
Eric Santa
Other
Gwendolyn Turner
Independent Director
Heiner Dreismann
Independent Director
Rashmi Kumar
Independent Director
Dennis Langer
Independent Director
Lee Newcomer
Independent Director
Colleen Reitan
Independent Director
Daniel Skovronsky
Independent Director
Daniel Spiegelman
No Data
  • All
  • Financials
  • Insiders
More
About MYGN
Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Webull offers kinds of Myriad Genetics, Inc. stock information, including NASDAQ:MYGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYGN stock methods without spending real money on the virtual paper trading platform.